Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis : profit tops expectations as pandemic impact ebbs

07/21/2021 | 03:22am EDT
FILE PHOTO: Logo is seen at new factory of Novartis in Stein

ZURICH (Reuters) - Swiss drugmaker Novartis beat second-quarter sales and profit expectations on Wednesday, while keeping its 2021 guidance unchanged, as disruption from the coronavirus pandemic waned.

"While demand is starting to return to pre-COVID-19 levels in most geographies and therapeutic areas, we still see a slight impact on parts of our business for example in oncology, generics and certain geographies," it said.

"We are assuming further easing of COVID-19 restrictions in the second half of the year with a positive impact on business dynamics."

Finance chief Harry Kirsch told reporters that the pandemic was still weighing, for instance, on cancer patients' diagnostic rates, which crimped sales of products sold via hospitals.

He estimated business was probably averaging 80-90% of pre-COVID levels, with strong divergences by category and country.

Novartis boosted core net profit by a fifth to $3.72 billion. Core operating income rose 18% to $4.35 billion. The gain of 13% in constant currencies was up around 4% excluding the impact of destocking in the year-earlier quarter after customers rushed to lay in supplies early last year, it said.

Sales in the three months through June rose 14% to $12.96 billion, a gain of 9% when stripping out currency fluctuations.

Analysts polled by Refinitiv had on average expected net profit of $3.46 billion on revenue of $12.52 billion.

Novartis said its key drug brands were performing well and its product development pipeline continued to progress.

It reiterated it expected 2021 sales to grow by a low- to mid-single digit percentage rate at constant currencies, with core operating income growing at a mid-single digit rate.

Its shares rose 2.2% in early trading, ahead of the European health care sector index, which was up 0.9%.

Vontobel analyst Stefan Schneider said results clearly beat expectations but the company's failure to upgrade its guidance "indicates that the pandemic situation has not yet returned fully to pre-pandemic levels and that the situation remains somewhat unpredictable due to the emerging variants".

(Reporting by Michael Shields; Editing by John Revill and Mark Potter)

By Michael Shields

ę Reuters 2021
All news about NOVARTIS AG
05:26aNOVARTIS AG : Buy rating from UBS
08/03IONIS PHARMACEUTICALS : discovered pelacarsen continues to advance as potential ..
08/03BAUSCH HEALTH : Reports Q2 Revenue US$2.1 Billion; Plans To Pursue An IPO of Sol..
08/03NOVARTIS : announces lift of partial clinical trial hold and plans to initiate a..
08/03Novartis Gets FDA Approval to Proceed With Trials for Muscular Atrophy Treatm..
08/03NOVARTIS : Says FDA Lifts Partial Hold on Clinical Trial of Spinal Muscular Atro..
08/03NOVARTIS : to Launch New Study of Neuromuscular Disease Drug After US FDA Lifts ..
08/03PRESS RELEASE : Novartis announces lift of partial -2-
08/03PRESS RELEASE : Novartis announces lift of partial clinical trial hold and plans..
08/03Novartis announces lift of partial clinical trial hold and plans to initiate ..
More news
Financials (USD)
Sales 2021 51 982 M - -
Net income 2021 9 881 M - -
Net Debt 2021 22 970 M - -
P/E ratio 2021 20,2x
Yield 2021 3,56%
Capitalization 225 B 225 B -
EV / Sales 2021 4,77x
EV / Sales 2022 4,46x
Nbr of Employees 109 000
Free-Float 87,4%
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 92,35 $
Average target price 105,60 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-0.20%224 638
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
NOVO NORDISK A/S36.67%213 138